Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects

Atherosclerosis

Volumn 149, Issue 1, 2000, Pages 91-97

  Heijmans, Bastiaan T ^a,b   Westendorp, Rudi G J ^b,c   Lagaay, A Margot ^b   Knook, Dick L ^a,b   Kluft, Cornelis ^a   Slagboom, P Eline ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Mortality; OxLDL; Paraoxonase; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MORTALITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; COHORT STUDIES; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; ESTERASES; FEMALE; GENOTYPE; HUMANS; MALE; NETHERLANDS; POLYMORPHISM, GENETIC; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0033995538     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00311-1     Document Type: Article

References (29)

1. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., Watson A.D., Lusis A.J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 91:1995;2488-2496.
2. Steinberg D., Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation. 95:1997;1062-1071.
3. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:1991;152-154.
4. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96:1995;2882-2891.
5. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394:1998;284-287.
6. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:1993;73-76.
7. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14:1996;334-336.
8. Garin M.C., James R.W., Dussoix P., Blanché H., Passa P., Froguel P., Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99:1997;62-66.
9. Mackness M.I., Arrol S., Mackness B., Durrington P.N. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet. 349:1997;851-852.
10. Ruiz J., Blanché H., James R.W., Garin M.C., Vaisse C., Charpentier G., Cohen N., Morabia A., Passa P., Froguel P. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
11. Pfohl M., Koch M., Enderle M.D., Kuhn R., Fullhase J., Karsch K.R., Haring H.U. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 48:1999;623-627.
12. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96:1995;3005-3008.
13. Zama T., Murata M., Matsubara Y., Kawano K., Aoki N., Yoshino H., Watanabe G., Ishikawa K., Ikeda Y. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler. Thromb. Vasc. Biol. 17:1997;3565-3569.
14. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;2257-2260.
15. Herrmann S.M., Blanc H., Poirier O., Arveiler D., Luc G., Evans A., Marques Vidal P., Bard J.M., Cambien F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 126:1996;299-303.
16. Antikainen M., Murtomäki S., Syvänne M., Pahlman R., Tahvanainen E., Jauhiainen M., Frick M.H., Ehnholm C. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98:1996;883-885.
17. Ombres D., Pannitteri G., Montali A., Candeloro A., Seccareccia F., Campagna F., Cantini R., Campa P.P., Ricci G., Arca M. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler. Thromb. Vasc. Biol. 18:1998;1611-1616.
18. Leviev I., Negro F., James R.W. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler. Thromb. Vasc. Biol. 17:1997;2935-2939.
19. Sanghera D.K., Saha N., Kamboh M.I. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis. 136:1998;217-223.
20. Weverling-Rijnsburger A.W., Blauw G.J., Lagaay A.M., Knook D.L., Meinders A.E., Westendorp R.G.J. Total cholesterol and risk of mortality in the oldest old. Lancet. 350:1997;1119-1123.
21. Heijmans B.T., Gussekloo J., Kluft C., Droog S., Lagaay A.M., Knook D.L., Westendorp R.G.J., Slagboom P.E. Mortality risk in men is associated with a common mutation in the methylene-tetrahydrofolate reductase gene (MTHFR). Eur. J. Hum. Genet. 7:1999;197-204.
22. Sambrook J, Fritsch EJ, Maniatis T, editors. Molecular Cloning: A Laboratory Manual, vol. 2, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
23. O'Dell S.D., Humphries S.E., Day I.N. Rapid methods for population-scale analysis for gene polymorphisms: the ACE gene as an example. Br. Heart J. 73:1995;368-371.
24. World Health Organization. International classification of diseases: manual of the international statistical classification of diseases, injuries, and causes of death. Geneva: World Health Organization, 1977.
25. Schneider S, Kueffer JM, Roessli D, Excoffier L. ARLEQUIN ver. 1.1: a software for population genetic data analysis. Geneva: Genetics and Biometry laboratory, University of Geneva, 1997.
26. Thompson E.A., Deeb S., Walker D., Motulsky A.G. The detection of linkage disequilibrium between closely linked markers: RFLPs at the AI-CIII apolipoprotein genes. Am. J. Hum. Genet. 42:1988;113-124.
27. Kluft C., Meijer P., Brussaard H.E., Krans H.M., Schuit A.J. Serum neopterin in acute coronary syndromes. Lancet. 349:1997;1253.
28. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 40:1997;1286-1292.
29. Van Lenten B.J., Hama S.Y., de Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M., La Du B.N., Fogelman A.M., Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96:1995;2758-2767.